Binaural Sound During Phacoemulsification and Posterior Chamber Lens Implantation in Geriatric Patients
- Sponsor
- Seoul National University Hospital
- Study ID
- NCT07609186
- Status
- Recruiting
Conditions
- Binaural Beats
- Cataract
- Geriatric Anesthesia
Eligibility Criteria
- Sex
- ALL
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- binaural beats — DEVICEThe auditory stimulus provided to the experimental group generates an interference wave (binaural beat) by applying a frequency difference of 1 to 4 Hz between the left and right ears. The stimulus consists of pure binaural beats without any additional background music. The volume is initiated at 60 dB, which is set to one level lower than the default output volume of the audio-generating device.
- sham earphone — DEVICEPatients will wear identical earphones to the experimental group, but no sound, binaural beats, or any other auditory stimulus will be provided during the procedure.
Study Details
The purpose of this study is to evaluate the effects of binaural beats on patient satisfaction and intraoperative comfort in patients aged 65 years or older undergoing cataract surgery (phacoemulsification and posterior chamber intraocular lens implantation) under monitored anesthesia care (MAC) with propofol. Participants are randomly assigned to either a binaural beat group or a control group. The binaural beat group will wear earphones and listen to binaural beats from the time they arrive at the operating room until the surgery is completed. The control group will wear identical earphones but will not receive any auditory stimulus. During the procedure, standard vital signs and the bispectral index (BIS) will be continuously monitored in both groups. Following the surgery, the investigators will assess the patients' overall satisfaction using a 7-point Likert scale. Secondary assessments include patient preference for the anesthesia method, intraoperative pain intensity, sedation level, anxiety level, and quality of life (EQ-VAS) measured by a visual analogue scale. Any surgery-related discomfort or adverse events will also be recorded and compared between the two groups.
Key Dates
- First listed
- May 27, 2026
- Start date
- Aug 7, 2025
- Status verified
- May 2026
- Primary completion
- Jul 1, 2026
- Completion
- Jul 8, 2026
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: binaural beatsPatients in this arm will wear earphones and receive binaural beat auditory stimulation continuously from the moment they arrive at the operating room until the end of the surgery. During the procedure, monitored anesthesia care (MAC) will be maintained using a propofol target-controlled infusion (TCI) at an effect-site concentration of 0.3 μg/mL.
- Sham Comparator: controlPatients in this arm will wear identical earphones to the experimental group from the moment they arrive at the operating room until the end of the surgery, but no sound or auditory stimulus will be provided. During the procedure, monitored anesthesia care (MAC) will be maintained using a propofol target-controlled infusion (TCI) at an effect-site concentration of 0.3 μg/mL.
Primary Outcome Measure
Overall Patient Satisfaction [ Time Frame: Immediately after surgery in the recovery room ]
Central Contacts
- Jeong-Hwa Seo, MD, PhD82-2-2072-0641
Related Studies
- Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence TomographyRecruiting · Oregon Health and Science University · Portland, Oregon
- Intraoperative OCT Guidance of Intraocular Surgery IIRecruiting · Duke University · Durham, North Carolina
- Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital PopulationPHASE4 · Recruiting · University of California, San Francisco · San Francisco, California
- Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood CataractPHASE4 · Recruiting · EyePoint Pharmaceuticals, Inc. · Huntington Beach, California